Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who fully understand the study and are willing to sign the consent form voluntarily.
- People aged 18 years or older.
- People with a specific type of lung cancer (non-small cell lung cancer, or NSCLC) that does not have certain genetic markers (EGFR wild-type, and no ALK or ROS1 gene fusions) — this includes both non-squamous and squamous subtypes — OR people with a type of breast cancer that tests negative for oestrogen receptors, progesterone receptors, and HER-2 (sometimes called triple-negative breast cancer).
- For the lung cancer group: people who have not previously received systemic treatment for advanced disease, OR if they had earlier treatment before or after surgery, at least 12 months must have passed before the cancer came back or spread. People in a special early safety portion of the trial must have already tried at least one standard treatment that did not work, or were unable to tolerate or were not suitable for it. The same rules apply to the breast cancer group, with the additional detail that if taxane-based chemotherapy was given before or after surgery, at least 12 months must have passed before the cancer returned or spread.
- People with a performance status score of 0 or 1 on the ECOG scale, meaning they are able to carry out daily activities with little or no difficulty.
- People who have at least one measurable tumour lesion as defined by standard imaging criteria (RECIST 1.1).
- People with an expected survival of at least 12 weeks.
- People able to provide tumour tissue samples — either stored samples or newly taken biopsy or surgical samples from a tumour site that has not been previously treated with radiation — for laboratory testing (confirm with trial site for specific sample requirements).
- Women of childbearing potential who agree to use effective contraception during the study and for 6 months after the last dose, and who have a negative pregnancy test within 3 days before the first dose; male participants must also agree to use effective contraception during the study and for 6 months after the last dose.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have received any approved or experimental anti-cancer treatment within 4 weeks before the start of the study treatment.
- People who have received certain immune-boosting treatments within 2 weeks before the start of the study treatment.
- People who have previously received any drug that targets PD-1, PD-L1, or VEGF (specific immune checkpoint or blood vessel pathways).
- People with certain abnormal blood or laboratory test results (confirm with trial site for specific values).
- People with a history of lung scarring (pulmonary fibrosis) or who currently have severely reduced lung function.
- People with chronic health conditions that are not well controlled.
- People who still have unresolved side effects from previous treatments.
- People with brain metastases (cancer that has spread to the brain) that are not well controlled.
- People with an active infection at the time of enrolment.
- People with conditions that put them at increased risk of bleeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
To evaluate the preliminary clinical efficacy of IMM2510 for Injection in combination with chemotherapy as first-line treatment in patients with stage IV metastatic or recurrent non-small cell lung cancer (NSCLC); To evaluate the preliminary clinical efficacy of IMM2510 for Injection in combination with nab-paclitaxel as first-line treatment in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 17 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.